References
- Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505–12.
- Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) inpatients with advanced renal cell carcinoma (RCC).
- Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2006;2(1):89–100.
- Dhanda R, Gondek K, Song J, et al. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24(18s):4534 (Abstract).
- Gore ME, Escudier B. Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology. 2006;20(6 suppl 5):19–25.
- Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.
- Motzer RJ, Rini B, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21):2516–2524.
- Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24(18s): LBA3 (Abstract).
- Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, inpatients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909–18.
- Hudes G, Carducci M, Tomczak P, et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24(18s): LBA4 (Abstract).
References
- American Cancer Society. Cancer Facts and Figures 2006. Atlanta: ACS; 2006. Available online at: www.cancer.org. Last accessed October 25, 2006.
- Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–2490.
- Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma: 1983–1993. Semin Oncol. 1995:2242–60.
- Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127–3132.
- Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial. J Clin Oncol. 2003;21:3133–3140.
- Fisher RJ, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl)S55–S57.
- Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alpha 2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol. 1993;11:1809–1816.
- Atzpodien J, Hännien Lopez E, Kirchner H, et al. Multi-institutional home-therapy trial of recombinant human interleukin-2 and interferon alpha-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995;13:497–501.
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004.
- Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000;60(7):1942–8.
- Iliopoulos O, Levy AP, Jiang C, et al. Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595–9.
- Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science. 2001;292(5516):464–8.
- Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–72.
- Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005;23(23):5386–403.
- Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326–34
- Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide antitumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo. Proc Am Assoc Cancer Res. 1999;40:301 (Abstract 1000).
- Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003;4(2):147–58.
- Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10(2):159–70.
- Gollob JA. Sorafenib: Scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005;4(3):167–74.
- Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST J Clin Oncol. 2004;22(22):4442–5.
- Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24.
- Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).